Skip to content
Screener

Rhythm Pharmaceuticals, Inc. RYTM Q2 2025 earnings

Reported August 5, 2025 · Before market open

Revenue$48.5MMiss by $2.8M
EPS-$0.75Miss by $0.09
Revenue estimate$51.3M
EPS estimate-$0.66

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$84.5M
EPS estimate-$0.72

Financials

Q2 2025

Income statement

See full
Revenue$48.5M+66.8%
Gross profit$43.0M+64.4%
Operating income-$45.3M-11.9%
Net income-$46.6M-44.5%
EPS (diluted)-$0.75-36.4%

Balance sheet

See full
Cash & equivalents$135.6M-16.1%
Total debt$114.0M+2,669%
Total equity-$11.9M-130%
Total assets$372.7M-2.4%

Cash flow

See full
Operating cash flow-$23.3M+19.8%
CapEx$238.3K—
Free cash flow-$29.2M-2.4%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$4.05B+64.0%
Enterprise value$4.03B+74.2%
P/S25.9×+1.7×

Profitability

See full
Gross margin89.2%+0.4pp
Operating margin-113.5%-41.0pp
Net margin-117.1%-41.1pp
FCF margin-73.7%-19.1pp

Returns & leverage

See full
Current ratio2.8×-3.7×

Segments

By segment

See full
Single reportable segment$48.5M+66.8%

FAQ

When did Rhythm Pharmaceuticals, Inc. report Q2 2025 earnings?
Rhythm Pharmaceuticals, Inc. (RYTM) reported Q2 2025 earnings on August 5, 2025 before market open.
What were Rhythm Pharmaceuticals, Inc.'s Q2 2025 revenue and EPS?
Rhythm Pharmaceuticals, Inc. reported revenue of $48.5M and eps of $-0.75 for Q2 2025.
Did Rhythm Pharmaceuticals, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $51.3M by $2.8M. EPS missed the consensus estimate of $-0.66 by $0.09.
How did Rhythm Pharmaceuticals, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 66.8% from $29.1M a year earlier and eps declined 36.4% from $-0.55.
Where can I find Rhythm Pharmaceuticals, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001558370-25-010176) and the 10-Q periodic report (0001558370-25-010302) directly on SEC EDGAR. The filing index links above go to sec.gov.